.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Minodronate is a heterocyclic nitrogen-containing bisphosphonate with high potency in inhibiting bone resorption, and is developed for clinical use in Japan. Minodronate has very high potency in inhibiting farnesyl pyrophosphate synthase, and shows lower affinity for bone matrix hydroxyapatite at both neutral and acidic pH. As a result, small amount of minodronate is deposited in bone but can exert strong anti-resorptive activity in vivo. In this review on minodronate, we summarize the mechanism of action, physico-chemical properties, effects on bone quality in animals, and effects on bone turnover, bone mineral density and fracture prevention, as well as safety in the treatment of patients with osteoporosis.
Keyword:
Heterocyclic nitrogen-containing bisphosphonate
Farnesyl pyrophosphate synthase
Hydroxyapatite affinity
Bone mineral density
Bone quality
Fracture prevention
期刊
IF:
3.6
论文数:
1.3W
被引数:
2.3W
机构
引用论文
Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys.png)
BONE.png)
BONEIF3.6
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptakeTRAFFIC
OAAI
TRAFFICIF2.5
OAAI分享收藏分享收藏分享收藏Analysis of the enzyme abnormality in eight cases of neonatal and infantile citrullinaemia in Japan
PREAI
分享收藏
查看更多内容